Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders

Inclusion Criteria Concurrent Medication: Allowed: * Maintenance antihormones, hormones, and glucocorticoids. Patients must have: * Histologically proven metastatic cancer including Kaposi's sarcoma and lymphoproliferative disorders to the skin or cutaneous sites. NOTE: * Primary basal or squamous cell cancer of the skin is allowed. * Failed both primary and secondary chemotherapy and/or immunotherapy protocols. * Measurable skin or cutaneous lesions. 4 Life expectancy of at least 20 weeks. Prior Medication: Required: * Prior therapy for cutaneous lesions from Kaposi's sarcoma or lymphoproliferative disorders. Allowed: * Prior maintenance steroids and hormone/antihormone therapy. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Active infections other than medically stable HIV infection. * Active congestive heart failure, any persistent arrhythmia or transient serious arrhythmia (ventricular tachycardia, sinoatrial arrest, etc.), or progressive cardiomyopathy. * Unstable blood pressure. * Seizures or other CNS disorders. * Severe unstable diabetes mellitus. * Coagulopathies. * Thrombotic disease. * Any other medical conditions that would prevent completion of study or produce significant risk to patient. Concurrent Medication: Excluded: * Concomitant chemotherapy or immunotherapy. * Ongoing corticosteroid therapy (unless maintenance). Patients with the following prior conditions are excluded: * History of active cardiopulmonary or respiratory disease. * History of sun hypersensitivity and photosensitive dermatoses. * History of allergy or hypersensitivity to cosmetics, toiletries, or other dermatological products.